HIVID Drug Patent Profile

When do Hivid patents expire, and when can generic versions of Hivid launch?

Hivid is a drug marketed by Roche and is included in one NDA.

The generic ingredient in HIVID is zalcitabine. Additional details are available on the zalcitabine profile page.

Summary for HIVID

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	116
Patent Applications:	4,205
DailyMed Link:	HIVID at DailyMed

US Patents and Regulatory Information for HIVID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992		DISCN	No	No
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992		DISCN	No	No

Expired US Patents for HIVID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992

International Patents for HIVID

See the table below for patents covering HIVID around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	87776	Anti-retroviral pharmaceutical compositions for preventing aids comprising 2',3'-dideoxycytidine
Ireland	862264
Hungary	T47856
Ireland	63001	Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2'3'-dideoxycytidine
Germany	3689221

Supplementary Protection Certificates for HIVID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0216511	94C0015	Belgium		PRODUCT NAME: GADODIAMIDE; NAT. REGISTRATION NO/DATE: NL 19253 19940425; FIRST REGISTRATION: GB - 0637/0015 19920925
0216511	SPC/GB95/003	United Kingdom		SPC/GB95/003:, EXPIRES: 20070406

HIVID Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of the HIV Drugs Market

Global Market Size and Growth

The global HIV drugs market is poised for significant growth over the coming years. As of 2023, the market size was approximately $34.13 billion, and it is expected to grow to $58.24 billion by 2032, registering a Compound Annual Growth Rate (CAGR) of 6.2% from 2024 to 2032[1][4].

Regional Dominance

North America is anticipated to dominate the HIV drugs market during the forecast period. In 2023, the North America market stood at $24.09 billion, driven by the high prevalence of HIV infections in the U.S. population. According to the Centers for Disease Control (CDC), approximately 1.2 million individuals were living with HIV in the U.S. as of 2018, which significantly increases the demand for HIV drugs[1].

Key Market Drivers

Several factors are driving the growth of the global HIV drugs market:

• Increased Prevalence of HIV Infections: The rising number of HIV cases globally is a primary driver.
• New Product Launches: Innovative treatments, such as combination HIV medicines and long-acting formulations, are enhancing patient outcomes and driving market growth.
• Greater Availability of Affordable Drugs: Increased access to affordable HIV treatments is another significant factor[1][3][4].

Market Segmentation

The combination HIV medicines segment is expected to lead the market during the forecast period. This segment includes advanced combination regimens and long-acting formulations that have significantly improved patient outcomes[1][3].

Key Players and Competitive Landscape

The global HIV drugs market is dominated by key players such as ViiV Healthcare, Gilead Sciences, Janssen Pharmaceuticals, Inc., and Merck. These companies are driving market growth through strong sales of antiretroviral drugs, new product launches, and strategic collaborations. For instance, Gilead Sciences Inc. and Merck Sharp & Dohme have collaborated on the co-development and co-commercialization of long-acting treatments combining Islatravir and Lenacapavir for HIV patients[1].

Gilead Sciences: A Market Leader

Gilead Sciences is a prominent player in the HIV drugs market. The company's HIV business delivered strong results in 2023, with revenues of $18.2 billion, a 6% year-over-year increase. Biktarvy, one of Gilead's flagship drugs, has demonstrated impressive share gains, with annualized revenues exceeding $12 billion and a market share of approximately 48% in the U.S. as of the fourth quarter of 2023[2].

Financial Performance and Projections

Gilead's HIV portfolio continues to show strong performance. Despite some quarterly variables, such as changes in channel mix and inventory dynamics, the overall demand trends remain strong. For 2024, Gilead expects HIV sales to grow approximately 4%, driven by annual treatment demand growth of 2 to 3%, Biktarvy market share gains, and continued double-digit growth in demand for HIV prevention[2].

Impact of Macroeconomic Factors

Macroeconomic factors significantly influence the global infectious disease therapeutics market, including the HIV drugs segment. Economic growth enhances healthcare budgets and infrastructure, leading to greater investment in research and development. Conversely, economic downturns can result in budget cuts and reduced spending on healthcare, potentially stalling innovation and limiting access to essential treatments. Inflation and currency fluctuations also affect drug pricing and market dynamics, increasing the cost of raw materials and manufacturing, and impacting international sales and profitability[3].

Public Health Initiatives and Awareness

Increased awareness regarding HIV/AIDS and enhanced global access to HIV care are crucial factors driving the market. Public health initiatives and substantial investments in research further solidify the prominence of the HIV segment in the infectious disease therapeutics landscape[1][3].

Challenges and Opportunities

While the market is growing, there are challenges to be addressed. For instance, the rising resistance to existing therapies necessitates continuous innovation and investment in new therapies. Additionally, economic fluctuations and changes in healthcare policies can impact market dynamics. However, these challenges also present opportunities for companies to develop new and innovative treatments, such as long-acting oral and injectable regimens, which are expected to drive future growth[1][3][4].

Illustrative Statistics

• Market Size: Expected to grow from $36.11 billion in 2024 to $58.24 billion by 2032[1].
• CAGR: 6.2% from 2024 to 2032[1].
• North America Market: $24.09 billion in 2023[1].
• Gilead's HIV Revenue: $18.2 billion in 2023, with Biktarvy contributing over $12 billion[2].
• Global Infectious Disease Therapeutics Market: Expected to be worth around $132.8 billion by 2033, with the HIV segment commanding a substantial market share of 29.12% as of 2023[3].

Expert Insights

"Gilead’s leadership in HIV is unmatched – with a solid commercial portfolio and robust pipeline of potentially best-in-class regimens to serve the daily oral, long-acting oral, and long-acting injectable markets," as noted by Gilead Sciences' executives, highlighting the company's strong position in the market[2].

Key Takeaways

• The global HIV drugs market is expected to grow significantly, driven by increased prevalence, new product launches, and greater availability of affordable drugs.
• North America dominates the market, with key players like Gilead Sciences and ViiV Healthcare leading the way.
• Macroeconomic factors and public health initiatives play crucial roles in market dynamics.
• Continuous innovation and investment in new therapies are essential to address rising resistance and changing market conditions.

Frequently Asked Questions (FAQs)

Q: What is the projected global market size for HIV drugs by 2032? A: The global HIV drugs market is expected to reach $58.24 billion by 2032[1].

Q: Which region dominates the HIV drugs market? A: North America dominates the HIV drugs market, with a market size of $24.09 billion in 2023[1].

Q: What are the key drivers of the HIV drugs market growth? A: The key drivers include the increased prevalence of HIV infections, new product launches, and the greater availability of affordable drugs[1][3][4].

Q: Which company is a market leader in the HIV drugs segment? A: Gilead Sciences is a prominent market leader, with its drug Biktarvy demonstrating strong market share gains and significant revenue contributions[2].

Q: How do macroeconomic factors impact the HIV drugs market? A: Macroeconomic factors such as economic growth, inflation, and currency fluctuations influence investment, pricing, and accessibility of HIV drugs[3].

Sources:

1. Fortune Business Insights - HIV Drugs Market Size & Growth | Global Report [2024-2032]
2. Gilead Sciences - Fourth Quarter and Full Year 2023 Prepared Remarks
3. Market.US - Infectious Disease Therapeutics Market Growth | CAGR of 6.8%
4. Precedence Research - HIV Drugs Market Size to Achieve USD 66.16 Billion by 2034